Only in North America, more than 2 millions of people are suffering from these both debilitating conditions.
More than 40% IBD patients do not tolerate or respond well to current therapies. Currently available medications alleviate inflammation but still do not prevent long term complications. There is a strong need to broaden the therapeutic arsenal with novel orally-administered therapeutic modalities, that could become great alternatives to the use of biologics.
The primary indication targeted by the Company is moderate-to-severe, active ulcerative colitis. Giiant’s lead compound, GT-2108 is a gut-restricted, colon-specific PDE4 prodrug inhibitor. GT-1908 is also a gut-restricted PDE4 inhibitor prodrug, able to deliver the active PDE4 inhibitor more proximally, making this candidate suitable for Crohn’s Disease treatment.
Table of pipeline
|Drug candidate||target||Gut-restricted||Tissue Specific||discovery||preclinical||phase 1||phase 2||phase 3|
Drug Hunting Club
giiant pharma is still looking for new GI-related technologies. The Company created a Drug Hunting Club to identify new promising opportunities to in-license. If you have a technology to propose aligned with our lead asset, please contact us